Edge
StocktwitsEarnings

Official STOCKTWITS Representative
$AXSM Q2 '26 Earnings Results & Recap
• Reported GAAP EPS of -$0.99 down -2.06% YoY
• Reported revenue of $218.38M up 45.54% YoY
• Axsome Therapeutics believes that its current cash is sufficient to fund anticipated operations into cash flow positivity, based on the current operating plan, though no specific financial targets were provided.7
